Mechanisms of sacubitril–valsartan benefit in HFrEF

Nature Reviews Cardiology, Published online: 19 September 2019; doi:10.1038/s41569-019-0282-2Two studies reveal new details of the mechanisms underlying the benefits of the angiotensin receptor–neprilysin inhibitor sacubitril–valsartan in patients with heart failure and reduced ejection fraction, suggesting that sacubitril–valsartan induces reverse cardiac remodelling but has no effect in reducing central aortic stiffness.
Source: Nature Reviews Cardiology - Category: Cardiology Authors: Source Type: research